Literature DB >> 23154565

First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component.

Gouji Toyokawa1, Kenichi Taguchi2, Taro Ohba1, Yosuke Morodomi1, Tomoyoshi Takenaka1, Fumihiko Hirai1, Masafumi Yamaguchi1, Takashi Seto1, Mitsuhiro Takenoyama1, Kenji Sugio3, Yukito Ichinose1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23154565     DOI： 10.1097/JTO.0b013e3182762bcb

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  21 in total

1.  Synchronous primary lung cancer presenting with small cell carcinoma and adenocarcinoma.

Authors:  Yoko Yamamoto; Ken Kodama; Hiroyuki Yamato; Masashi Takeda; Hiroyuki Takamori; Takahiro Karasuno
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-31       Impact factor: 1.520

2.  Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.

Authors:  Taro Ohba; Gouji Toyokawa; Atsushi Osoegawa; Fumihiko Hirai; Masafumi Yamaguchi; Ken-Ichi Taguchi; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose; Kenji Sugio
Journal:  Surg Today       Date:  2015-12-28       Impact factor: 2.549

3.  Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Authors:  Birgitta Hiddinga; Karen Zwaenepoel; Annelies Janssens; Jan Van Meerbeeck; Patrick Pauwels
Journal:  Oncotarget       Date:  2022-06-01

Review 4.  Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

Authors:  Rita Dorantes-Heredia; José Manuel Ruiz-Morales; Fernando Cano-García
Journal:  Transl Lung Cancer Res       Date:  2016-08

5.  Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.

Authors:  Jianfei Zhu; Ling Cai; Haoxian Yang; Yinsheng Wen; Junye Wang; Tiehua Rong; Jianyong Shao; Lanjun Zhang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

Review 6.  Treating ALK-positive non-small cell lung cancer.

Authors:  Dimitrios C Ziogas; Anna Tsiara; Georgios Tsironis; Maria Lykka; Michalis Liontos; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Ann Transl Med       Date:  2018-04

7.  Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report.

Authors:  Qiong Sun; Jian-Yu Wu; Shun-Chang Jiao
Journal:  Oncol Lett       Date:  2014-08-21       Impact factor: 2.967

Review 8.  Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.

Authors:  Antonio Passaro; Chiara Lazzari; Niki Karachaliou; Gianluca Spitaleri; Alessia Pochesci; Chiara Catania; Rafael Rosell; Filippo de Marinis
Journal:  Onco Targets Ther       Date:  2016-10-17       Impact factor: 4.147

9.  Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor.

Authors:  Masayuki Nakajima; Naoki Uchiyama; Rie Shigemasa; Takeshi Matsumura; Ryota Matsuoka; Akihiro Nomura
Journal:  Intern Med       Date:  2016-11-01       Impact factor: 1.271

10.  Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung.

Authors:  Agnes Balla; Farrah Khan; Kenneth J Hampel; Dara L Aisner; Nikoletta Sidiropoulos
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.